Ardea Biosciences, Inc. (RDEA)

[surf1944]

Ardea Biosciences to Present Results from a Phase 2a Study of RDEA594 at the 2009 ACR/ARHP Annual Scientific Meeting
Press Release
Source: Ardea Biosciences, Inc.
On Wednesday September 30, 2009, 8:30 am EDT

Companies:Ardea Biosciences, Inc.
SAN DIEGO--(BUSINESS WIRE)--Ardea Biosciences, Inc. (Nasdaq: RDEA - News) today announced that it will present results from a Phase 2a, proof-of-concept study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, at the 2009 American College of Rheumatology (ACR) / Association of Rheumatology Health Professionals (ARHP) Annual Scientific Meeting in Philadelphia, Pennsylvania.

Previously disclosed interim results will be updated to include final single-agent cohort data, as well as data demonstrating RDEA594’s ability to lower serum urate to less than 6.0 mg/dL in patients with mild to moderate renal insufficiency, which was the majority of patients randomized to RDEA594. In addition, the company will provide an update on improved drug formulations and will present data from a preclinical drug-drug interaction study demonstrating RDEA594’s potential to be used in combination with allopurinol and febuxostat (Uloric®, Takeda Pharmaceutical Company Limited; Adenuric®, Ipsen), both of which lower serum urate via a different mechanism of action than RDEA594.

Presentation Details are as follows:

Poster Title: RDEA594, a Novel Uricosuric Agent, Significantly Reduced Serum Urate Levels and Was Well Tolerated in a Phase 2a Pilot Study in Hyperuricemic Gout Patients
Session Title: Treatment and Outcomes
Date/Time: Monday, October 19, 2009 from 9:00 AM – 6:00 PM Eastern Time
Presentation: Monday, October 19, 2009, 9:00 AM Eastern Time
Poster: 1105
Location: Pennsylvania Convention Center – Hall D

Poster Title: Evaluation of Drug-Drug Interaction Potential Between RDEA594, Allopurinol and Febuxostat in Preclinical Species
Session Title: Treatment and Outcomes
Date/Time: Monday, October 19, 2009 from 9:00 AM – 6:00 PM Eastern Time
Presentation: Monday, October 19, 2009, 9:00 AM Eastern Time
Poster: 1102
Location: Pennsylvania Convention Center – Hall D


About RDEA594 and RDEA684

RDEA594, our lead product candidate for the treatment of hyperuricemia and gout, is a selective URAT1 transporter inhibitor that is in Phase 2 development as a single agent and in combination with the approved xanthine oxidase inhibitors, allopurinol and febuxostat (Uloric®, Takeda Pharmaceutical Company Limited; Adenuric®, Ipsen). Over 300 people have safely received RDEA594, either by direct administration or through administration of RDEA806, its prodrug. We have selected a next-generation URAT1 inhibitor, RDEA684, as a development candidate and expect to begin a Phase 1 study of RDEA684 in 2010. Based on preclinical results, RDEA684 demonstrates many of the same positive attributes as RDEA594, but with more than 170-times greater potency against the URAT1 transporter.